Author disclosures: Dr. Runowicz receives speaking fees and research support from Cytyc Corporation (First Cyte Ductal Lavage). Dr. Rubinstein is on the speaker's bureau for Myriad Genetic Laboratories, Inc. Dr. D'Orsi is a medical consultant to GE Medical Systems and R2 Technology, Inc. Dr. Feig is on the medical advisory board of R2 Technology, Inc., a company that sells a computer-aided detection device for mammography; he does not receive any financial remuneration or grant support from the company. Dr. Giger is a shareholder in R2 Technology, Inc.; she also has received unrestricted research support from the company in the past.
Article first published online: 31 DEC 2008
Copyright © 2003 American Cancer Society
CA: A Cancer Journal for Clinicians
Volume 53, Issue 3, pages 141–169, May/June 2003
How to Cite
Smith, R. A., Saslow, D., Sawyer, K. A., Burke, W., Costanza, M. E., Evans, W. P., Foster, R. S., Hendrick, E., Eyre, H. J. and Sener, S. (2003), American Cancer Society Guidelines for Breast Cancer Screening: Update 2003. CA: A Cancer Journal for Clinicians, 53: 141–169. doi: 10.3322/canjclin.53.3.141
This article is available online at: http://CAonline.AmCancerSoc.org
- Issue published online: 31 DEC 2008
- Article first published online: 31 DEC 2008
In 2003, the American Cancer Society updated its guidelines for early detection of breast cancer based on recommendations from a formal review of evidence and a recent workshop. The new screening recommendations address screening mammography, physical examination, screening older women and women with comorbid conditions, screening women at high risk, and new screening technologies.